As of Mar 27
| +0.03 / +0.54%|
The 2 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 3.00. The median estimate represents a +7.53% increase from the last price of 5.58.
The current consensus among 2 polled investment analysts is to Buy stock in Corcept Therapeutics Inc. This rating has held steady since March, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.